{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:21:38Z","timestamp":1786443698052,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>The purpose of this study was to determine the rate and risk factors for the development of irreversible hepatotoxicity after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) and synthetic hepatic dysfunction. Two hundred fifty-one consecutive patients with HCC and hepatic dysfunction who underwent 443 TACE procedures from 2005 to 2010 were retrospectively reviewed. The included patients met one of the following criteria: a pre-TACE bilirubin level \u2265 2 mg\/dL, an international normalized ratio (INR) &gt; 1.5, a creatinine level &gt; 1.2 mg\/dL, a platelet count \u2264 60,000\/mL, a Model for End-Stage Liver Disease (MELD) score &gt; 15, Child-Turcotte-Pugh class B or C, ascites, or portal vein thrombosis. Hepatotoxicity was defined as new or worsening ascites, encephalopathy, or grade 3 or 4 toxicity (bilirubin, aspartate aminotransferase, alanine aminotransferase, creatinine, or INR) according to the National Cancer Institute Common Terminology Criteria for Adverse Events. The rate and risk factors for death or urgent liver transplantation within 6 weeks of TACE and irreversible hepatotoxicity were determined with a generalized estimating equation analysis. Reversible hepatotoxicity developed after 90 procedures (20%) in 78 patients (31%). Irreversible hepatotoxicity developed after 41 procedures (9%) in 37 patients (15%). Six patients (2%) underwent urgent liver transplantation, and 11 (4%) died within 6 weeks of TACE. Patients at increased risk for procedure-related mortality or urgent liver transplantation within 6 weeks of TACE had a baseline serum bilirubin level \u2265 4.0 mg\/dL (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.01), an elevated INR (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), hypoalbuminemia with an albumin level &lt; 2.0 g\/L (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.01), a serum creatinine level &gt; 2.0 mg\/dL (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02), large ascites (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002), encephalopathy (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.005), or a MELD score \u2265 20 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). In conclusion, TACE can be performed safely in patients with baseline hepatic dysfunction. However, a poor hepatic reserve increases the risk of irreversible hepatotoxicity, which may lead to death or the need for urgent liver transplantation. Liver Transpl 19:164\u2013173, 2013. \u00a9 2012 AASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.23552","type":"journal-article","created":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T22:32:01Z","timestamp":1348525921000},"page":"164-173","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":73,"title":["Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction"],"prefix":"10.1097","volume":"19","author":[{"given":"Elisabeth R.","family":"Garwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Fidelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Kerlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Y.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20250124","doi-asserted-by":"crossref","first-page":"12451255","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma.","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"R2-7-20250124","doi-asserted-by":"crossref","first-page":"10241030","DOI":"10.1016\/j.jvir.2010.03.005","article-title":"Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization.","volume":"21","author":"Wible","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"R3-7-20250124","doi-asserted-by":"crossref","first-page":"12091218","DOI":"10.1097\/01.RVI.0000128123.04554.C1","article-title":"Comparison of MELD and ChildPugh scores to predict survival after chemoembolization for hepatocellular carcinoma.","volume":"15","author":"Brown","year":"2004","journal-title":"J Vasc Interv Radiol"},{"key":"RU4-7-20250124","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1148\/radiol.2241011262","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma: metaanalysis of randomized controlled trials.","volume":"224","author":"Camma","year":"2002","journal-title":"Radiology"},{"issue":"suppl 2","key":"R5-7-20250124","first-page":"S98S108","article-title":"Is the treatment of hepatocellular carcinoma on the waiting list necessary?","volume":"17","author":"Majno","year":"2011","journal-title":"Liver Transpl"},{"issue":"suppl 2","key":"R6-7-20250124","first-page":"S109S116","article-title":"Does a patient qualify for liver transplantation after the downstaging of hepatocellular carcinoma?","volume":"17","author":"Yao","year":"2011","journal-title":"Liver Transpl"},{"key":"R7-7-20250124","doi-asserted-by":"crossref","first-page":"262278","DOI":"10.1002\/lt.21999","article-title":"Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States.","volume":"16","author":"Pomfret","year":"2010","journal-title":"Liver Transpl"},{"key":"R8-7-20250124","doi-asserted-by":"crossref","first-page":"212220","DOI":"10.1016\/j.ctrv.2010.07.006","article-title":"Evolving strategies for the management of intermediatestage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.","volume":"37","author":"Raoul","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"R10-7-20250124","first-page":"12561261","article-title":"Groupe dEtude et de Traitement du Carcinome Hepatocellulaire.","volume":"332","year":"1995","journal-title":"N Engl J Med"},{"key":"R11-7-20250124","doi-asserted-by":"crossref","first-page":"17471752","DOI":"10.1002\/cncr.10407","article-title":"A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma.","volume":"94","author":"Chan","year":"2002","journal-title":"Cancer"},{"key":"R13-7-20250124","doi-asserted-by":"crossref","first-page":"413420","DOI":"10.1245\/s10434-010-1321-8","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study.","volume":"18","author":"Luo","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R14-7-20250124","doi-asserted-by":"crossref","first-page":"16531659","DOI":"10.1097\/01.RVI.0000182185.47500.7A","article-title":"Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.","volume":"16","author":"Georgiades","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"R16-7-20250124","doi-asserted-by":"crossref","first-page":"271277","DOI":"10.1016\/j.crad.2010.01.018","article-title":"Transcatheter arterial chemolipiodol infusion for unresectable hepatocellular carcinoma in 96 highrisk patients.","volume":"65","author":"Yoon","year":"2010","journal-title":"Clin Radiol"},{"key":"R17-7-20250124","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1097\/01.RVI.0000195074.43474.2F","article-title":"Chemoembolization in patients at high risk: results and complications.","volume":"17","author":"Kiely","year":"2006","journal-title":"J Vasc Interv Radiol"},{"key":"R18-7-20250124","doi-asserted-by":"crossref","first-page":"15171526","DOI":"10.1016\/j.jvir.2007.07.035","article-title":"Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk.","volume":"18","author":"Kothary","year":"2007","journal-title":"J Vasc Interv Radiol"},{"key":"R19-7-20250124","doi-asserted-by":"crossref","first-page":"659664","DOI":"10.1016\/j.amjsurg.2010.07.021","article-title":"Periprocedural complications by ChildPugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center.","volume":"200","author":"Russell","year":"2010","journal-title":"Am J Surg"},{"key":"R21-7-20250124","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23552","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23552","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201302000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:28:46Z","timestamp":1737739726000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201302000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.23552","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}